Skip to main content
Cyber Week Sale - Get 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

  • Eisai Co., Ltd. presented new data on anti-tau antibody etalanetug at the 18th Clinical Trials on Alzheimer's Disease Conference.
  • The Phase Ib/II study reported an eMTBR-tau243 reduction of 62% at 3 months and 89% at 9 months after etalanetug administration.
  • Plasma eMTBR-tau243 levels were reduced by 78% at 3 months and over 90% at 9 months, as observed in the study.
  • In September 2025, etalanetug received Fast Track designation from the U.S. Food and Drug Administration .
Insights by Ground AI

52 Articles

Rutland HeraldRutland Herald
+51 Reposted by 51 other sources
Center

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase Ib/II study

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 55% of the sources are Center
55% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Tuesday, December 2, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Rutland, Vermont icon

Rutland, Vermont

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal